GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » ROC (Joel Greenblatt) %

Biodesix (Biodesix) ROC (Joel Greenblatt) % : -95.41% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Biodesix ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Biodesix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -95.41%.

The historical rank and industry rank for Biodesix's ROC (Joel Greenblatt) % or its related term are showing as below:

BDSX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1675.07   Med: -789.99   Max: -207.45
Current: -207.45

During the past 6 years, Biodesix's highest ROC (Joel Greenblatt) % was -207.45%. The lowest was -1675.07%. And the median was -789.99%.

BDSX's ROC (Joel Greenblatt) % is ranked worse than
75.54% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: -13.95 vs BDSX: -207.45

Biodesix's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 28.20% per year.


Biodesix ROC (Joel Greenblatt) % Historical Data

The historical data trend for Biodesix's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix ROC (Joel Greenblatt) % Chart

Biodesix Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -1,580.27 -526.11 -697.29 -882.69 -221.74

Biodesix Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -859.58 -541.17 -237.66 -139.87 -95.41

Competitive Comparison of Biodesix's ROC (Joel Greenblatt) %

For the Diagnostics & Research subindustry, Biodesix's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biodesix's ROC (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Biodesix's ROC (Joel Greenblatt) % falls into.



Biodesix ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.777 + 0 + 3.268) - (6.587 + 0.659 + 24.24)
=-22.441

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.679 + 0 + 5.72) - (6.784 + 0.324 + 26.005)
=-19.714

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Biodesix for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-27.24/( ( (27.488 + max(-22.441, 0)) + (29.612 + max(-19.714, 0)) )/ 2 )
=-27.24/( ( 27.488 + 29.612 )/ 2 )
=-27.24/28.55
=-95.41 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biodesix  (NAS:BDSX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Biodesix ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Biodesix's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biodesix (Biodesix) Business Description

Traded in Other Exchanges
N/A
Address
2970 Wilderness Place, Suite 100, Boulder, CO, USA, 80301
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Executives
Scott Hutton director, officer: President & CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane officer: Chief Commercial Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano officer: Chief Development Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie officer: CFO, Sec'y & Treasurer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez officer: Chief Accounting Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Jon Faiz Kayyem director 5964 LA PLACE COURT, CARLSBAD CA 92008
Kennedy Lawrence T. Jr director, 10 percent owner C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Ryan H Siurek officer: Chief Accounting Officer 6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
John Patience director, 10 percent owner, other: Chairman 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Georgantas Robert William Iii director, officer: SVP, Rsrch & Trans'l Science 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139